全球穿戴式連續血糖監測儀市場 - 2025 至 2033 年

2024 年全球穿戴式連續血糖監測儀 (CGM) 市場規模達到 45.7 億美元，預計到 2033 年將達到 166 億美元，在 2025-2033 年預測期內的複合年成長率為 15.5%。

穿戴式連續血糖監測儀 (CGM) 是用於即時監測血糖水平的先進醫療設備。它們提供全天血糖波動的連續即時資料，與提供單點讀數的傳統血糖儀相比，提供更詳細、更一致的血糖水平圖像。

市場動態：

促進因素與約束因素

糖尿病盛行率上升

全球糖尿病盛行率的大幅上升推動了穿戴式連續血糖監測 (CGM) 設備市場的成長。根據世界衛生組織的數據，糖尿病患者數量急劇增加，從 1990 年的 2 億增加到 2022 年的 8.3 億，其中成長最快的是中低收入國家。隨著糖尿病盛行率的上升，對血糖水平進行有效、即時監測的需求變得更加迫切。穿戴式 CGM 為持續血糖監測提供了一種有效、非侵入性的解決方案，幫助患者更好地管理病情並降低嚴重併發症的風險。

未經治療或管理不當的糖尿病影響非常嚴重，可導致失明、腎衰竭、心臟病、中風和下肢截肢等病症。光是 2021 年，糖尿病和糖尿病相關腎病變就導致超過 200 萬人死亡，高血糖導致心血管死亡人數約 11%。根據這些統計數據，隨著醫療保健系統和患者尋求更積極的方式來管理糖尿病和預防危及生命的併發症，對連續血糖監測設備的需求預計會增加。

穿戴式 CGM 在為個人提供即時資料方面變得越來越重要，這些數據可以幫助及時採取干涉措施、降低併發症風險並改善糖尿病患者的整體生活品質。糖尿病管理日益成長的需求是推動穿戴式 CGM 市場擴張的關鍵因素。

感測器更換成本高

穿戴式連續血糖監測 (CGM) 設備的感測器壽命短和更換成本會給消費者帶來經濟負擔，從而嚴重限制市場。大多數 CGM 感測器需要每 7 到 14 天更換一次，導致頻繁的持續費用迅速累積，使長期使用成本高昂。

目錄

第 1 章：方法與範圍

第 2 章：定義與概述

第 3 章：執行摘要

第 4 章：動態

• 影響因素
  • 驅動程式
    • 糖尿病盛行率上升
  • 限制
    • 感測器更換成本高
  • 機會
• 影響分析

第5章：戰略洞察與產業展望

• 市場領導者和先驅者
  • 新興先鋒和傑出參與者
  • 擁有最大銷售品牌的成熟領導者
  • 擁有成熟產品的市場領導者
• CXO 觀點
• 最新進展與突破
• 案例研究/正在進行的研究
• 監管和報銷情況
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲
• 波特五力分析
• 供應鏈分析
• 專利分析
• SWOT 分析
• 未滿足的需求和差距
• 市場進入和擴張的推薦策略
• 情境分析：最佳情況、基本情況和最壞情況預測
• 定價分析和價格動態
• 關鍵意見領袖

第 6 章：按類型

• 1 型糖尿病
• 2 型糖尿病

第 7 章：按組件

• 感應器
• 發射器和接收器
• 顯示器
• 其他

第 8 章：依年齡層

• 孩子們
• 成年人
• 長老

第 9 章：按最終用戶

• 家庭護理設置
• 醫院和診所
• 其他

第 10 章：按地區

• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 歐洲其他地區
• 南美洲
  • 巴西
  • 阿根廷
  • 南美洲其他地區
• 亞太
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 中東和非洲

第 11 章：競爭格局

• 競爭格局
• 市場定位/佔有率分析
• 併購分析

第 12 章：公司簡介

• Afon Technology
• 公司概況
• 產品組合
  • 產品描述
  • 產品關鍵績效指標 (KPI)
  • 歷史和預測產品銷售量
  • 產品銷售量
• 財務概覽
  • 公司收入
  • 地區收入佔有率
  • 收入預測
• 主要進展
  • 合併與收購
  • 關鍵產品開發活動
  • 監管部門批准等
• SWOT 分析
• Abbott
• Senseonics
• Ascensia Diabetes Care Holdings AG.
• A. Menarini Diagnostics srl
• Murata Manufacturing Co., Ltd.
• Dexcom, Inc.
• Tandem Diabetes Care, Inc.
• Medtronic
• Byram Healthcare Centers, Inc.
• Similar data will be provided for each market player.

第 13 章：附錄

The global wearable continuous glucose monitors (CGM) market reached US$ 4.57 billion in 2024 and is expected to reach US$ 16.60 billion by 2033, growing at a CAGR of 15.5% during the forecast period 2025-2033.

Wearable Continuous Glucose Monitors (CGMs) are advanced medical devices used to monitor glucose levels in real time. They provide continuous, real-time data on glucose fluctuations throughout the day, offering a more detailed and consistent picture of glucose levels compared to traditional blood glucose meters that provide single-point readings.

Market Dynamics: Drivers & Restraints

Rising Prevalence of Diabetes

The significant rise in the global prevalence of diabetes is driving the growth of the wearable continuous glucose monitoring (CGM) devices market. The number of people living with diabetes has increased dramatically, from 200 million in 1990 to 830 million in 2022, with the most rapid rise occurring in low- and middle-income countries according to the World Health Organization. As the prevalence of diabetes grows, the need for effective, real-time monitoring of glucose levels becomes even more critical. Wearable CGMs offer an efficient, non-invasive solution for continuous glucose monitoring, helping patients better manage their condition and reduce the risk of severe complications.

The impact of untreated or poorly managed diabetes is severe, leading to conditions such as blindness, kidney failure, heart attacks, strokes, and lower limb amputations. In 2021 alone, diabetes and diabetes-related kidney disease were responsible for over 2 million deaths, with high blood glucose contributing to around 11% of cardiovascular deaths. Given these statistics, the demand for continuous glucose monitoring devices is expected to increase as healthcare systems and patients seek more proactive ways to manage diabetes and prevent life-threatening complications.

Wearable CGMs are becoming increasingly vital in providing individuals with real-time data that can inform timely interventions, reduce the risk of complications, and improve the overall quality of life for people with diabetes. This growing need for diabetes management is a key factor driving the expansion of the wearable CGM market.

High Sensor Replacement Costs

The short sensor lifespan and replacement costs of wearable continuous glucose monitoring (CGM) devices can significantly restrain the market by creating a financial burden for consumers. Most CGM sensors need to be replaced every 7 to 14 days, resulting in frequent ongoing expenses that can quickly add up, making long-term use costly.

Segment Analysis

The global wearable continuous glucose monitors (CGM) market is segmented based on type, components, age group, end-user, and region.

Product Type:

Sensors segment is expected to dominate the global wearable continuous glucose monitors (cgm) market share

The sensors component segment is expected to dominate the wearable continuous glucose monitoring (CGM) devices market due to their essential role in providing real-time, accurate glucose measurements. Sensors are the core technology behind CGMs, as they continuously monitor blood glucose levels through interstitial fluid, offering users detailed and up-to-date information. With the increasing demand for more precise, real-time monitoring, advancements in sensor technology have enabled the development of more accurate, smaller, and longer-lasting devices.

Moreover, innovations in sensor design, such as improved accuracy, reduced size, and extended wear times, are driving the segment's growth. As people with diabetes seek more efficient and convenient ways to manage their condition, the demand for CGM systems with advanced sensors is growing. This makes the sensors segment a key driver in the wearable CGM market, as it directly impacts the overall performance and reliability of these devices.

Geographical Analysis

North America is expected to hold a significant position in the global wearable continuous glucose monitors (CGM) market share

North America is expected to dominate the wearable continuous glucose monitoring (CGM) devices market due to a combination of factors. The increasing technological advancements, rising number of diabetic patients, and increasing number of product launches are expected to hold the region in the dominant position in the global market.

The region has a high prevalence of diabetes, driving the demand for advanced diabetes management solutions. The high incidence of diabetes in North America, particularly in the United States, is significantly driving the demand for wearable continuous glucose monitoring (CGM) devices. In 2021, an estimated 29.7 million people, or 8.9% of the U.S. population, were diagnosed with diabetes. This growing prevalence, including 352,000 children and adolescents under the age of 20, highlights the urgent need for effective and convenient ways to monitor glucose levels continuously. As the number of diabetes cases continues to rise, the demand for solutions like CGMs, which provide real-time, accurate glucose data and help individuals manage their condition more effectively.

Additionally, market players are increasingly innovating the advanced wearable CGMs that are gaining approvals from the Food and Drug Administration (FDA). For instance, in March and June 2024, Dexcom and Abbott received clearance from the Food and Drug Administration (FDA) for their over-the-counter (OTC) continuous glucose monitors. While these devices utilize the same hardware as previous CGMs, they are designed for a different group of users, individuals who do not require insulin. Increasing approvals for products, such as over-the-counter continuous glucose monitors from companies are expected to drive the North American market by expanding accessibility to glucose monitoring solutions. This will cater to a broader range of users, including those without insulin dependence. Thus, the above factors are expected to hold the region in the dominant position.

Competitive Landscape

The major global players in the wearable continuous glucose monitors (CGM) market include Afon Technology, Abbott, Senseonics, Ascensia Diabetes Care Holdings AG., A. Menarini Diagnostics srl, Murata Manufacturing Co., Ltd., Dexcom, Inc., Tandem Diabetes Care, Inc., Medtronic and Byram Healthcare Centers, Inc. among others.

Key Developments

• In September 2024, Abbott launched its latest wearable, the Lingo continuous glucose monitor, now available for over-the-counter purchase. Unlike traditional devices designed for diabetics, Lingo is tailored for health-conscious individuals who want to track their glucose levels without requiring prior medical approval.
• In February 2024, Know Labs, Inc. unveiled the KnowU, its wearable non-invasive continuous glucose monitor (CGM). The company first introduced the prototype in June 2023, with the KnowU being the outcome of an accelerated eight-month development process.
• In January 2025, Samsung announced that it is developing a highly anticipated feature for wearable technology: a non-invasive continuous glucose monitor.
• In April 2024, Senseonics Holdings, Inc. announced that their Eversense device has received the integrated CGM (iCGM) designation from the U.S. Food and Drug Administration (FDA).

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Wearable Continuous Glucose Monitors (CGM) Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Component
• 3.3. Snippet by Age Group
• 3.4. Snippet by End User
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Prevalence of Diabetes
  • 4.1.2. Restraints
    • 4.1.2.1. High Sensor Replacement Costs
  • 4.1.3. Opportunity
• 4.2. Impact Analysis

5. Strategic Insights and Industry Outlook

• 5.1. Market Leaders and Pioneers
  • 5.1.1. Emerging Pioneers and Prominent Players
  • 5.1.2. Established leaders with largest selling Brand
  • 5.1.3. Market leaders with established Product
• 5.2. CXO Perspectives
• 5.3. Latest Developments and Breakthroughs
• 5.4. Case Studies/Ongoing Research
• 5.5. Regulatory and Reimbursement Landscape
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa
• 5.6. Porter's Five Force Analysis
• 5.7. Supply Chain Analysis
• 5.8. Patent Analysis
• 5.9. SWOT Analysis
• 5.10. Unmet Needs and Gaps
• 5.11. Recommended Strategies for Market Entry and Expansion
• 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 5.13. Pricing Analysis and Price Dynamics
• 5.14. Key Opinion Leaders

6. By Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Type 1 Diabetes*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Type 2 Diabetes

7. By Component

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
  • 7.1.2. Market Attractiveness Index, By Component
• 7.2. Sensors*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Transmitters and Receivers
• 7.4. Displays
• 7.5. Others

8. By Age Group

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 8.1.2. Market Attractiveness Index, By Age Group
• 8.2. Children*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Adults
• 8.4. Elders

9. By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.1.2. Market Attractiveness Index, By End User
• 9.2. Homecare Settings*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Hospitals & Clinics
• 9.4. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. U.K.
    • 10.3.7.3. France
    • 10.3.7.4. Spain
    • 10.3.7.5. Italy
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

• 12.1. Afon Technology*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio
    • 12.1.2.1. Product Description
    • 12.1.2.2. Product Key Performance Indicators (KPIs)
    • 12.1.2.3. Historic and Forecasted Product Sales
    • 12.1.2.4. Product Sales Volume
  • 12.1.3. Financial Overview
    • 12.1.3.1. Company Revenue's
    • 12.1.3.2. Geographical Revenue Shares
    • 12.1.3.3. Revenue Forecasts
  • 12.1.4. Key Developments
    • 12.1.4.1. Mergers & Acquisitions
    • 12.1.4.2. Key Product Development Activities
    • 12.1.4.3. Regulatory Approvals etc.
  • 12.1.5. SWOT Analysis
• 12.2. Abbott
• 12.3. Senseonics
• 12.4. Ascensia Diabetes Care Holdings AG.
• 12.5. A. Menarini Diagnostics srl
• 12.6. Murata Manufacturing Co., Ltd.
• 12.7. Dexcom, Inc.
• 12.8. Tandem Diabetes Care, Inc.
• 12.9. Medtronic
• 12.10. Byram Healthcare Centers, Inc.
• Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us